Tempus AI (NASDAQ:TEM) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised Tempus AI’s price target to $66 from $56 and maintained a “buy” rating, implying about 12.4% upside. Analysts remain mixed overall, with a consensus “hold” rating and $69.33 target.
• Tempus AI reported quarterly revenue of $382.5 million, up 21.6% year over year, and an adjusted EPS loss of $0.04 that beat expectations of a $0.14 loss.
• The stock opened at $58.74 and has traded between $40.77 and $104.32 over the past year. Insiders sold roughly $57 million of shares in the last quarter, while institutional investors own about 24.2% of the company.

Tempus AI (NASDAQ:TEM - Get Free Report) had its target price raised by equities research analysts at HC Wainwright from $56.00 to $66.00 in a report issued on Friday, MarketBeat reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 12.36% from the company's current price.

A number of other research firms have also commented on TEM. Raymond James Financial set a $80.00 price objective on Tempus AI in a research note on Wednesday, September 2nd. Weiss Ratings downgraded shares of Tempus AI from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 27th. Rothschild & Co Redburn initiated coverage on shares of Tempus AI in a report on Tuesday. They issued a "neutral" rating and a $67.00 target price on the stock. Piper Sandler raised shares of Tempus AI from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $56.00 to $76.00 in a research note on Tuesday, September 1st. Finally, Cantor Fitzgerald assumed coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They set an "overweight" rating and a $80.00 price target for the company. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $69.33.

Tempus AI Trading Down 4.1%

Shares of Tempus AI stock opened at $58.74 on Friday. Tempus AI has a 1 year low of $40.77 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The business has a 50 day moving average price of $55.99 and a 200 day moving average price of $52.28. The company has a market capitalization of $10.60 billion, a P/E ratio of -40.79 and a beta of 3.72.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI's quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.22) EPS. Sell-side analysts anticipate that Tempus AI will post -1.38 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In related news, Director Nadja West sold 3,000 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the transaction, the director owned 31,981 shares of the company's stock, valued at approximately $2,206,689. This represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the transaction, the chief executive officer directly owned 47,420 shares in the company, valued at approximately $3,319,400. This represents a 23.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,043,988 shares of company stock valued at $56,963,417 in the last quarter. Insiders own 24.26% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Victory Capital Management Inc. raised its position in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company's stock valued at $894,000 after purchasing an additional 162 shares in the last quarter. Truist Financial Corp increased its stake in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company's stock worth $209,000 after buying an additional 194 shares during the last quarter. SeaCrest Wealth Management LLC increased its stake in shares of Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company's stock worth $524,000 after buying an additional 229 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Tempus AI by 64.5% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company's stock valued at $53,000 after acquiring an additional 256 shares in the last quarter. Finally, Pathstone Holdings LLC raised its holdings in Tempus AI by 1.4% in the third quarter. Pathstone Holdings LLC now owns 18,338 shares of the company's stock valued at $1,480,000 after acquiring an additional 261 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.